Results 181 to 190 of about 102,885 (334)

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki   +24 more
wiley   +1 more source

Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment Following Switch From Topical Corticosteroids for Trunk and Extremity Rash in Atopic Dermatitis

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory disease characterized by recurrent remissions and relapses. Topical anti‐inflammatory steroids are commonly used for treatment, but their long‐term use poses concerns because of potential side effects. Delgocitinib ointment, a Janus kinase inhibitor, has demonstrated efficacy in several clinical
Masatoshi Abe   +5 more
wiley   +1 more source

Prevalence, Comorbidities, and Current Management of Chronic Spontaneous Urticaria in Japan: Retrospective Claims Database Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Chronic spontaneous urticaria (CSU) affects 0.5%–1.0% of the population worldwide. However, information on the prevalence, comorbidities, and treatment patterns of CSU in Japan is limited. This observational study consisted of a cross‐sectional and longitudinal part.
Atsushi Fukunaga   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy